GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » PCL Inc (XKRX:241820) » Definitions » EV-to-EBITDA

PCL (XKRX:241820) EV-to-EBITDA : -4.38 (As of Nov. 10, 2024)


View and export this data going back to 2017. Start your Free Trial

What is PCL EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, PCL's enterprise value is ₩46,642 Mil. PCL's EBITDA for the trailing twelve months (TTM) ended in Jun. 2024 was ₩-10,641 Mil. Therefore, PCL's EV-to-EBITDA for today is -4.38.

The historical rank and industry rank for PCL's EV-to-EBITDA or its related term are showing as below:

XKRX:241820' s EV-to-EBITDA Range Over the Past 10 Years
Min: -145.44   Med: -12.48   Max: 92.62
Current: -4.46

During the past 10 years, the highest EV-to-EBITDA of PCL was 92.62. The lowest was -145.44. And the median was -12.48.

XKRX:241820's EV-to-EBITDA is ranked worse than
100% of 477 companies
in the Medical Devices & Instruments industry
Industry Median: 16.06 vs XKRX:241820: -4.46

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-11-10), PCL's stock price is ₩760.00. PCL's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was ₩-393.890. Therefore, PCL's PE Ratio (TTM) for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).


PCL EV-to-EBITDA Historical Data

The historical data trend for PCL's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PCL EV-to-EBITDA Chart

PCL Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -10.85 17.30 -13.60 64.24 -12.93

PCL Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.06 -5.62 -12.93 -6.80 -5.68

Competitive Comparison of PCL's EV-to-EBITDA

For the Medical Devices subindustry, PCL's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PCL's EV-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, PCL's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where PCL's EV-to-EBITDA falls into.



PCL EV-to-EBITDA Calculation

PCL's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=46642.240/-10640.767
=-4.38

PCL's current Enterprise Value is ₩46,642 Mil.
PCL's EBITDA for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩-10,641 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


PCL  (XKRX:241820) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

PCL's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=760.00/-393.890
=At Loss

PCL's share price for today is ₩760.00.
PCL's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩-393.890.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).

Please read Which price ratio outperforms the enterprise multiple?


PCL EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of PCL's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


PCL Business Description

Traded in Other Exchanges
N/A
Address
Star Valley No. 701, 99, Digitalro, 9gi, Geumcheongu, Seoul, KOR, 08510
PCL Inc is engaged in the development of vitro diagnostics products by SG Cap technology used in immobilizing disease biomarkers. It offers blood testing kit, multiplex antigen detection kits, and ultra-low volume non-contact liquid handling.In addition, the company offers platform services, such as sol-gel spotting service that immobilizes the customer's requested material using the SolB reagent; and SG ID service, which provides customers with a molecule of interest immobilized in the SolB reagent and identified.

PCL Headlines

No Headlines